The CC Chemokine MCP-1/CCL2 in Pancreatic Cancer Progression: Regulation of Expression and Potential Mechanisms of Antimalignant Activity

Paolo Monti, Biagio Eugenio Leone, Federica Marchesi, Gianpaolo Balzano, Alessandro Zerbi, Francesca Scaltrini, Claudio Pasquali, Giliola Calori, Francesca Pessi, Cosimo Sperti, Valerio Di Carlo, Paola Allavena, Lorenzo Piemonti

Research output: Contribution to journalArticle

147 Citations (Scopus)

Abstract

The aim of this study was to discover whether MCP-1/CCL2, a CC chemokine able to attract macrophages, is expressed in human pancreatic cancer and how it modulates cancer progression. All primary tumors were tested, and 6 of 14 pancreatic cancer cell lines were constitutively secreted CCL2. Analysis of the regulation demonstrated that the expression of CCL2 was significantly elevated and in a synergistic manner by IFN-γ, tumor necrosis factor α, and interleukin 1β. By immunohistochemistry and in situ hybridization, CCL2 production was confirmed in neoplastic ducts from surgical specimens. Serum levels of CCL2 in pancreatic cancer patients were significantly higher than in normal healthy subjects (P <0.0001). Patients with high circulating levels of CCL2 had significantly higher survival rate than low CCL2 producers. Serum CCL2 levels positively correlated with tumor macrophage infiltration and inversely correlated with tumor proliferative activity (Ki67 expression). A direct effect of CCL2 on tumor cells is to be excluded, either because primary tumors as well as cell lines have no detectable CCL2 receptor (CCR2) and because addition of CCL2 on tumor cells in vitro did not modify cell cycle progression or apoptosis. In vitro, a model of tumor microenvironment showed a direct antiproliferative and proapoptotic activity of monocytes toward pancreatic cancer cell, which is mediated at least in part by interleukin 1β. Moreover, other proinflammatory cytokines such as tumor necrosis factor α and IFN-γ appeared able to induce apoptosis and to reduce the proliferative rate of pancreatic cancer. On the whole, the results presented in our investigation suggest that CCL2 could be a relevant negative regulator of pancreatic cancer progression.

Original languageEnglish
Pages (from-to)7451-7461
Number of pages11
JournalCancer Research
Volume63
Issue number21
Publication statusPublished - Nov 1 2003

Fingerprint

CC Chemokines
Pancreatic Neoplasms
Neoplasms
Interleukin-1
Tumor Necrosis Factor-alpha
CCR2 Receptors
Macrophages
Apoptosis
Cell Line
Tumor Microenvironment
Serum
In Situ Hybridization
Monocytes
Healthy Volunteers
Cell Cycle
Survival Rate
Immunohistochemistry
Cytokines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The CC Chemokine MCP-1/CCL2 in Pancreatic Cancer Progression : Regulation of Expression and Potential Mechanisms of Antimalignant Activity. / Monti, Paolo; Leone, Biagio Eugenio; Marchesi, Federica; Balzano, Gianpaolo; Zerbi, Alessandro; Scaltrini, Francesca; Pasquali, Claudio; Calori, Giliola; Pessi, Francesca; Sperti, Cosimo; Di Carlo, Valerio; Allavena, Paola; Piemonti, Lorenzo.

In: Cancer Research, Vol. 63, No. 21, 01.11.2003, p. 7451-7461.

Research output: Contribution to journalArticle

Monti, Paolo ; Leone, Biagio Eugenio ; Marchesi, Federica ; Balzano, Gianpaolo ; Zerbi, Alessandro ; Scaltrini, Francesca ; Pasquali, Claudio ; Calori, Giliola ; Pessi, Francesca ; Sperti, Cosimo ; Di Carlo, Valerio ; Allavena, Paola ; Piemonti, Lorenzo. / The CC Chemokine MCP-1/CCL2 in Pancreatic Cancer Progression : Regulation of Expression and Potential Mechanisms of Antimalignant Activity. In: Cancer Research. 2003 ; Vol. 63, No. 21. pp. 7451-7461.
@article{313c3b5052254913b85f4430c7110613,
title = "The CC Chemokine MCP-1/CCL2 in Pancreatic Cancer Progression: Regulation of Expression and Potential Mechanisms of Antimalignant Activity",
abstract = "The aim of this study was to discover whether MCP-1/CCL2, a CC chemokine able to attract macrophages, is expressed in human pancreatic cancer and how it modulates cancer progression. All primary tumors were tested, and 6 of 14 pancreatic cancer cell lines were constitutively secreted CCL2. Analysis of the regulation demonstrated that the expression of CCL2 was significantly elevated and in a synergistic manner by IFN-γ, tumor necrosis factor α, and interleukin 1β. By immunohistochemistry and in situ hybridization, CCL2 production was confirmed in neoplastic ducts from surgical specimens. Serum levels of CCL2 in pancreatic cancer patients were significantly higher than in normal healthy subjects (P <0.0001). Patients with high circulating levels of CCL2 had significantly higher survival rate than low CCL2 producers. Serum CCL2 levels positively correlated with tumor macrophage infiltration and inversely correlated with tumor proliferative activity (Ki67 expression). A direct effect of CCL2 on tumor cells is to be excluded, either because primary tumors as well as cell lines have no detectable CCL2 receptor (CCR2) and because addition of CCL2 on tumor cells in vitro did not modify cell cycle progression or apoptosis. In vitro, a model of tumor microenvironment showed a direct antiproliferative and proapoptotic activity of monocytes toward pancreatic cancer cell, which is mediated at least in part by interleukin 1β. Moreover, other proinflammatory cytokines such as tumor necrosis factor α and IFN-γ appeared able to induce apoptosis and to reduce the proliferative rate of pancreatic cancer. On the whole, the results presented in our investigation suggest that CCL2 could be a relevant negative regulator of pancreatic cancer progression.",
author = "Paolo Monti and Leone, {Biagio Eugenio} and Federica Marchesi and Gianpaolo Balzano and Alessandro Zerbi and Francesca Scaltrini and Claudio Pasquali and Giliola Calori and Francesca Pessi and Cosimo Sperti and {Di Carlo}, Valerio and Paola Allavena and Lorenzo Piemonti",
year = "2003",
month = "11",
day = "1",
language = "English",
volume = "63",
pages = "7451--7461",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - The CC Chemokine MCP-1/CCL2 in Pancreatic Cancer Progression

T2 - Regulation of Expression and Potential Mechanisms of Antimalignant Activity

AU - Monti, Paolo

AU - Leone, Biagio Eugenio

AU - Marchesi, Federica

AU - Balzano, Gianpaolo

AU - Zerbi, Alessandro

AU - Scaltrini, Francesca

AU - Pasquali, Claudio

AU - Calori, Giliola

AU - Pessi, Francesca

AU - Sperti, Cosimo

AU - Di Carlo, Valerio

AU - Allavena, Paola

AU - Piemonti, Lorenzo

PY - 2003/11/1

Y1 - 2003/11/1

N2 - The aim of this study was to discover whether MCP-1/CCL2, a CC chemokine able to attract macrophages, is expressed in human pancreatic cancer and how it modulates cancer progression. All primary tumors were tested, and 6 of 14 pancreatic cancer cell lines were constitutively secreted CCL2. Analysis of the regulation demonstrated that the expression of CCL2 was significantly elevated and in a synergistic manner by IFN-γ, tumor necrosis factor α, and interleukin 1β. By immunohistochemistry and in situ hybridization, CCL2 production was confirmed in neoplastic ducts from surgical specimens. Serum levels of CCL2 in pancreatic cancer patients were significantly higher than in normal healthy subjects (P <0.0001). Patients with high circulating levels of CCL2 had significantly higher survival rate than low CCL2 producers. Serum CCL2 levels positively correlated with tumor macrophage infiltration and inversely correlated with tumor proliferative activity (Ki67 expression). A direct effect of CCL2 on tumor cells is to be excluded, either because primary tumors as well as cell lines have no detectable CCL2 receptor (CCR2) and because addition of CCL2 on tumor cells in vitro did not modify cell cycle progression or apoptosis. In vitro, a model of tumor microenvironment showed a direct antiproliferative and proapoptotic activity of monocytes toward pancreatic cancer cell, which is mediated at least in part by interleukin 1β. Moreover, other proinflammatory cytokines such as tumor necrosis factor α and IFN-γ appeared able to induce apoptosis and to reduce the proliferative rate of pancreatic cancer. On the whole, the results presented in our investigation suggest that CCL2 could be a relevant negative regulator of pancreatic cancer progression.

AB - The aim of this study was to discover whether MCP-1/CCL2, a CC chemokine able to attract macrophages, is expressed in human pancreatic cancer and how it modulates cancer progression. All primary tumors were tested, and 6 of 14 pancreatic cancer cell lines were constitutively secreted CCL2. Analysis of the regulation demonstrated that the expression of CCL2 was significantly elevated and in a synergistic manner by IFN-γ, tumor necrosis factor α, and interleukin 1β. By immunohistochemistry and in situ hybridization, CCL2 production was confirmed in neoplastic ducts from surgical specimens. Serum levels of CCL2 in pancreatic cancer patients were significantly higher than in normal healthy subjects (P <0.0001). Patients with high circulating levels of CCL2 had significantly higher survival rate than low CCL2 producers. Serum CCL2 levels positively correlated with tumor macrophage infiltration and inversely correlated with tumor proliferative activity (Ki67 expression). A direct effect of CCL2 on tumor cells is to be excluded, either because primary tumors as well as cell lines have no detectable CCL2 receptor (CCR2) and because addition of CCL2 on tumor cells in vitro did not modify cell cycle progression or apoptosis. In vitro, a model of tumor microenvironment showed a direct antiproliferative and proapoptotic activity of monocytes toward pancreatic cancer cell, which is mediated at least in part by interleukin 1β. Moreover, other proinflammatory cytokines such as tumor necrosis factor α and IFN-γ appeared able to induce apoptosis and to reduce the proliferative rate of pancreatic cancer. On the whole, the results presented in our investigation suggest that CCL2 could be a relevant negative regulator of pancreatic cancer progression.

UR - http://www.scopus.com/inward/record.url?scp=10744234018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744234018&partnerID=8YFLogxK

M3 - Article

C2 - 14612545

AN - SCOPUS:10744234018

VL - 63

SP - 7451

EP - 7461

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 21

ER -